Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

NasdaqGS - Nasdaq Real Time Price USD

Adaptive Biotechnologies Corporation (ADPT)

Compare

8.26

+0.10

+(1.23%)

At close: February 28 at 4:00:02 PM EST

8.51

+0.25

+(3.03%)

After hours: February 28 at 7:49:34 PM EST

Adaptive Biotechnologies price target raised to $12 from $10 at Scotiabank

Scotiabank analyst Sung Ji Nam raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $12 from $10 and keeps an Outperform rating on the shares. The company ended FY24 on a “strong note,” beating expectations across the board, the analyst tells investors. The firm continues to think there is significant growth potential ahead for the company’s minimal residual disease business. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try

TipRanks 15 days ago

ADPT
+1.23%
Adaptive Biotechnologies Full Year 2024 Earnings: EPS Beats Expectations

Adaptive Biotechnologies ( NASDAQ:ADPT ) Full Year 2024 Results Key Financial Results Revenue: US$179.0m (up 5.1% from...

Simply Wall St. 16 days ago

ADPT
+1.23%
Adaptive Biotechnologies (ADPT) Moves to Buy: Rationale Behind the Upgrade

Adaptive Biotechnologies (ADPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 17 days ago

ADPT
+1.23%
Q4 2024 Adaptive Biotechnologies Corp Earnings Call

Q4 2024 Adaptive Biotechnologies Corp Earnings Call

Thomson Reuters StreetEvents 17 days ago

ADPT
+1.23%
NEO
Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?

Here is how Adaptive Biotechnologies (ADPT) and Castle Biosciences, Inc. (CSTL) have performed compared to their sector so far this year.

Zacks 17 days ago

ADPT
+1.23%
CSTL
Adaptive Biotechnologies Corp (ADPT) Q4 2024 Earnings Call Highlights: Strong MRD Revenue ...

Adaptive Biotechnologies Corp (ADPT) reports robust MRD revenue growth and strategic partnerships, despite a decline in Immune Medicine revenue.

GuruFocus.com 17 days ago

ADPT
+1.23%
Adaptive Biotechnologies (ADPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Adaptive Biotechnologies (ADPT) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks 18 days ago

ADPT
+1.23%
Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Tops Revenue Estimates

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 11.54% and 2.23%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 18 days ago

ADPT
+1.23%
Adaptive Biotechnologies: Q4 Earnings Snapshot

The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 26 cents per share. The life-sciences research company posted revenue of $47.5 million in the period, also beating Street forecasts. Five analysts surveyed by Zacks expected $46.4 million.

Associated Press Finance 18 days ago

ADPT
+1.23%
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results

SEATTLE, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December 31, 2024. “2024 was a year of strong execution, marked by key catalysts achieved in our MRD business and advancements in our Immu

GlobeNewswire 18 days ago

ADPT
+1.23%
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences. BTIG 12th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UTParticipating on Wednesday, Februa

GlobeNewswire 24 days ago

ADPT
+1.23%
PhaseV and Alimentiv to support execution of adaptive clinical trials for GI

The partnership will integrate PhaseV's adaptive clinical trial technology with Alimentiv's comprehensive GI CRO services.

Clinical Trials Arena 25 days ago

ADPT
+1.23%
The 5.4% return this week takes Adaptive Biotechnologies' (NASDAQ:ADPT) shareholders one-year gains to 99%

The simplest way to invest in stocks is to buy exchange traded funds. But one can do better than that by picking better...

Simply Wall St. last month

ADPT
+1.23%
Why Adaptive Biotechnologies Corporation (ADPT) Is Skyrocketing Now

We recently compiled a list of the Why These 15 Stocks Are Skyrocketing in 2025. In this article, we are going to take a look at where Adaptive Biotechnologies Corporation (NASDAQ:ADPT) stands against the other stocks that are skyrocketing now. The market has started to favor smaller companies in 2025, and stocks between $1 billion and […]

Insider Monkey last month

ADPT
+1.23%
Why Is Andreas Halvorsen Bullish On Adaptive Biotechnologies Corporation (ADPT) Now?

We recently compiled a list of the Billionaire Andreas Halvorsen’s Top 15 Long-Term Stock Picks. In this article, we are going to take a look at where Adaptive Biotechnologies Corporation (NASDAQ:ADPT) stands against Andreas Halvorsen’s other long-term stock picks. Andreas Halvorsen is a prominent Norwegian hedge fund manager and the co-founder of Viking Global, one of […]

Insider Monkey last month

ADPT
+1.23%
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025

SEATTLE, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the fourth quarter and full year 2024 after market close on Tuesday, February 11, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time /

GlobeNewswire last month

ADPT
+1.23%
Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?

Here is how Adaptive Biotechnologies (ADPT) and Bio-Rad Laboratories (BIO) have performed compared to their sector so far this year.

Zacks last month

ADPT
+1.23%
BIO-B
Adaptive Biotechnologies (ADPT) Soars 18.0%: Is Further Upside Left in the Stock?

Adaptive Biotechnologies (ADPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks last month

ADPT
+1.23%
ACLX
Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients

Pairing Adaptive Biotechnologies’ clonoSEQ MRD results with NeoGenomics’ COMPASS and CHART assessment services empowers clinicians and patients with meaningful insights across the treatment continuumSEATTLE and FORT MYERS, Fla., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, and NeoGenomics, Inc. (N

GlobeNewswire last month

ADPT
+1.23%
NEO
Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025

SEATTLE, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today that the new Medicare Clinical Laboratory Fee Schedule (CLFS) rate for its next-generation sequencing (NGS)-based clonoSEQ® test for minimal – or measurable – residual disease (MRD) assessment is now in effect as of January 1,

GlobeNewswire last month

ADPT
+1.23%

Performance Overview

Return	ADPT	S&P 500
YTD	+37.78%	+1.24%
1-Year	+99.04%	+17.45%
3-Year	-42.76%	+36.14%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Adaptive Biotechnologies Corporation (ADPT)

Adaptive Biotechnologies price target raised to $12 from $10 at Scotiabank

Adaptive Biotechnologies Full Year 2024 Earnings: EPS Beats Expectations

Adaptive Biotechnologies (ADPT) Moves to Buy: Rationale Behind the Upgrade

Q4 2024 Adaptive Biotechnologies Corp Earnings Call

Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?

Adaptive Biotechnologies Corp (ADPT) Q4 2024 Earnings Call Highlights: Strong MRD Revenue ...

Adaptive Biotechnologies (ADPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Tops Revenue Estimates

Adaptive Biotechnologies: Q4 Earnings Snapshot

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

PhaseV and Alimentiv to support execution of adaptive clinical trials for GI

The 5.4% return this week takes Adaptive Biotechnologies' (NASDAQ:ADPT) shareholders one-year gains to 99%

Why Adaptive Biotechnologies Corporation (ADPT) Is Skyrocketing Now

Why Is Andreas Halvorsen Bullish On Adaptive Biotechnologies Corporation (ADPT) Now?

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025

Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?

Adaptive Biotechnologies (ADPT) Soars 18.0%: Is Further Upside Left in the Stock?

Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients

Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025

Performance Overview